Mona Desai, MD
Infectious Disease · Greenwood, INNPI 1356503205
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,882 of the $2,127 with a category attached, or 88.5%. It is spread thinly across 31 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations.
Across 131 payments — averaging $16.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$364
- Merck$266
- Insmed, Inc.$222
- Viiv Healthcare Company$197
- Paratek Pharmaceuticals, Inc.$169
- Shionogi Inc$152
- plus $757 from 25 others
What the payments were for
- Food & beverage$1,88288%
- Education$24512%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 31 | $364 |
| Merck | 17 | $266 |
| Insmed, Inc. | 11 | $222 |
| Viiv Healthcare Company | 12 | $197 |
| Paratek Pharmaceuticals, Inc. | 11 | $169 |
| Shionogi Inc | 8 | $152 |
| Astellas Pharma US Inc | 6 | $109 |
| AbbVie | 6 | $106 |
| Janssen Products, LP | 1 | $72 |
| Cumberland Pharmaceuticals, Inc. | 3 | $59 |
| Dynavax Technologies Corporation | 3 | $57 |
| Aimmune Therapeutics, Inc. | 2 | $40 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $34 |
| Cormedix Inc. | 1 | $26 |
| Bayer | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Melinta Therapeutics, LLC | 1 | $19 |
| Theratechnologies Inc. | 1 | $18 |
| Almatica Pharma LLC | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Amgen | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $15 |
| Novartis | 1 | $14 |
| Viatris Specialty LLC | 1 | $14 |
| Nabriva Therapeutics, PLC | 1 | $14 |
| Mayne Pharma Commercial LLC | 1 | $14 |
| Pfizer | 1 | $13 |
| La Jolla Pharmaceutical Company | 1 | $13 |
| Boehringer Ingelheim | 1 | $13 |
| Novo Nordisk | 1 | $12 |
| Lilly USA, LLC | 1 | $11 |
How this compares
$2,127 in reported general payments places this provider in the 80th percentile of 152 infectious disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuzyraOmadacycline Tosylate | 24 | $335,367 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 15 | $228,605 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 34 | $148,081 |
| TivicayDolutegravir Sodium | 27 | $84,615 |
| DescovyEmtricitabine/Tenofov Alafenam | 23 | $54,201 |
| Rifabutin | 35 | $22,985 |
| Voriconazole | 21 | $9,653 |
| Ethambutol Hcl | 43 | $4,150 |
| Vancomycin Hcl | 12 | $1,404 |
| Azithromycin | 57 | $956 |
| Clarithromycin | 11 | $759 |
| Methenamine Hippurate | 13 | $529 |
| Cephalexin | 20 | $213 |
| Doxycycline Hyclate | 13 | $196 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 15 | $150 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Paratek Pharmaceuticals, Inc.Nuzyra | $169 | $335,36724 claims |
| Insmed, Inc.Arikayce | $222 | $228,60515 claims |
| GileadBiktarvy, Descovy | $364 | $202,28357 claims |
| Viiv Healthcare CompanyTivicay | $197 | $84,61527 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 152 infectious disease providers in Indiana.
Other infectious disease in Greenwood
- Aliya HaiderGreenwood$3K
- David CoxGreenwood$2K
- Timothy FransonZionsville$303K
- Donald TherasseZionsville$75K
- Anwer JaffriTerre Haute$63K
- Jason BaileyFort Wayne$60K
- Markian BochanCarmel$54K
- Samir GuptaIndianapolis$53K
- Erica Kaufman WestDyer$48K
- Tracey IkerdCarmel$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.